High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

Author： Horio Akiyo  

Publisher： Springer Publishing Company

ISSN： 1341-9625

Source： International Journal of Clinical Oncology, Vol.17, Iss.2, 2012-04, pp. : 131-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

By Rodrigues M. J.   Peron J.   Frnel J.-S.   Vano Y.-A.   Wassermann J.   Debled M.   Picaud F.   Albiges L.   Vincent-Salomon A.   Cottu P. H.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 916-924

Oxford University Press

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

By Lamond Nathan   Skedgel Chris   Rayson Daniel   Lethbridge Lynn   Younis Tallal  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1115-1123

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite